-
1
-
-
0347093576
-
Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003
-
Price, B.; Ware, A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am. J. Epidemiol. 2004, 159, 107-112.
-
(2004)
Am. J. Epidemiol.
, vol.159
, pp. 107-112
-
-
Price, B.1
Ware, A.2
-
2
-
-
0032938943
-
The European mesothelioma epidemic
-
Peto, J.; Decarli, A.; La Vecchia, C.; Levi, F.; Negri, E. The European mesothelioma epidemic. Br. J. Cancer 1999, 79, 666-672.
-
(1999)
Br. J. Cancer.
, vol.79
, pp. 666-672
-
-
Peto, J.1
Decarli, A.2
la Vecchia, C.3
Levi, F.4
Negri, E.5
-
3
-
-
0033856964
-
Environmental exposure to asbestos and risk of pleural mesothelioma: Review and meta-analysis
-
Bourdès, V.; Boffetta, P.; Pisani, P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur. J. Epidemiol. 2000, 16, 411-417.
-
(2000)
Eur. J. Epidemiol.
, vol.16
, pp. 411-417
-
-
Bourdès, V.1
Boffetta, P.2
Pisani, P.3
-
4
-
-
0031919717
-
Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships
-
Hansen, J.; de Klerk, N.H.; Musk, A.W.; Hobbs, M.S.T. Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships. Am. J. Respir. Crit. Care Med. 1998, 157, 69-75.
-
(1998)
Am. J. Respir. Crit. Care Med.
, vol.157
, pp. 69-75
-
-
Hansen, J.1
de Klerk, N.H.2
Musk, A.W.3
Hobbs, M.S.T.4
-
5
-
-
33748444562
-
Cytogenetic and molecular genetic changes in malignant mesothelioma
-
Musti, M.; Kettunen, E.; Dragonieri, S.; Lindholm, P.; Cavone, D.; Serio, G.; Knuutila, S. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet. Cytogenet. 2006, 170, 9-15.
-
(2006)
Cancer Genet. Cytogenet.
, vol.170
, pp. 9-15
-
-
Musti, M.1
Kettunen, E.2
Dragonieri, S.3
Lindholm, P.4
Cavone, D.5
Serio, G.6
Knuutila, S.7
-
6
-
-
0041471258
-
Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma
-
Shin, H.J.; Shin, D.M.; Tarco, E.; Sneige, N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer 2003, 99, 233-239.
-
(2003)
Cancer
, vol.99
, pp. 233-239
-
-
Shin, H.J.1
Shin, D.M.2
Tarco, E.3
Sneige, N.4
-
7
-
-
77951177646
-
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
-
Scherpereel, A.; Astoul, P.; Baas, P.; Berghmans, T.; Clayson, H.; de Vuyst, P.; Dienemann, H.; Galateau-Salle, F.; Hennequin, C.; Hillerdal, G.; Le Péchoux, C.; Mutti, L.; Pairon, J.C.; Stahel, R.; van Houtte, P.; van Meerbeeck, J.; Waller, D.; Weder, W. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir J. 2010, 35, 479-495.
-
(2010)
Eur. Respir J.
, vol.35
, pp. 479-495
-
-
Scherpereel, A.1
Astoul, P.2
Baas, P.3
Berghmans, T.4
Clayson, H.5
de Vuyst, P.6
Dienemann, H.7
Galateau-Salle, F.8
Hennequin, C.9
Hillerdal, G.10
le Péchoux, C.11
Mutti, L.12
Pairon, J.C.13
Stahel, R.14
van Houtte, P.15
van Meerbeeck, J.16
Waller, D.17
Weder, W.18
-
8
-
-
34548259390
-
Multidisciplinary treatment of malignant pleural mesothelioma
-
Cresoli, G.L.; Gridelli, C.; Santoro, A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007, 12, 850-863.
-
(2007)
Oncologist
, vol.12
, pp. 850-863
-
-
Cresoli, G.L.1
Gridelli, C.2
Santoro, A.3
-
9
-
-
79952259392
-
Advances in diagnosis and treatment of malignant mesothelioma
-
Scagliotti, G.V.; Selvaggi G. Advances in diagnosis and treatment of malignant mesothelioma. Oncol. Rev. 2007, 1, 91-102.
-
(2007)
Oncol. Rev.
, vol.1
, pp. 91-102
-
-
Scagliotti, G.V.1
Selvaggi, G.2
-
10
-
-
0035100888
-
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
-
Biomarkers Definitions Working Group
-
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
-
(2001)
Clin. Pharmacol. Ther.
, vol.69
, pp. 89-95
-
-
-
11
-
-
0031217594
-
Mechanisms of fiber-induced genotoxicity
-
Jaurand, M.C. Mechanisms of fiber-induced genotoxicity. Environ. Health Perspect. 1997, 5, 1073-1084.
-
(1997)
Environ. Health Perspect.
, vol.5
, pp. 1073-1084
-
-
Jaurand, M.C.1
-
12
-
-
0036144596
-
Distinct spectrum of mutations induced by crocidolite asbestos: Clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo
-
Unfried, K.; Schurkes, C.; Abel, J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res. 2002, 62, 99-104.
-
(2002)
Cancer Res
, vol.62
, pp. 99-104
-
-
Unfried, K.1
Schurkes, C.2
Abel, J.3
-
13
-
-
0027399969
-
Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induced targeted G.C → T.A transversions in simian kidney cells
-
Moriya, M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induced targeted G.C → T.A transversions in simian kidney cells. Proc. Natl. Acad. Sci. USA 1993, 90, 1122-1126.
-
(1993)
Proc. Natl. Acad. Sci. USA.
, vol.90
, pp. 1122-1126
-
-
Moriya, M.1
-
14
-
-
33846331650
-
Oxidative stress and cancer: Have we moved forward
-
Halliwell, B. Oxidative stress and cancer: have we moved forward? Biochem. J. 2007, 401, 1-11.
-
(2007)
Biochem. J.
, vol.401
, pp. 1-11
-
-
Halliwell, B.1
-
15
-
-
0032462852
-
Can oxidative DNA damage be used as a biomarker of cancer risk in human? Problems, resolutions and preliminary results from nutritional supplementation studies
-
Halliwell, B. Can oxidative DNA damage be used as a biomarker of cancer risk in human? Problems, resolutions and preliminary results from nutritional supplementation studies. Free Radical Res. 1998, 29, 469-486.
-
(1998)
Free Radical Res
, vol.29
, pp. 469-486
-
-
Halliwell, B.1
-
16
-
-
33750411466
-
Relationship between Asbestos Exposures and 8-Hydroxydeoxyguanosine Levels in Leukocytic DNA of Workers at a Chinese Asbestosmaterial Plant
-
Takahashi, K.; Pan, G.; Kasai, H.; Hanaoka, T.; Feng, Y.; Liu, N.; Zhang, S.; Xu, Z.; Tsuda, T.; Yamato, H.; Higashi, T.; Okubo, T. Relationship between Asbestos Exposures and 8-Hydroxydeoxyguanosine Levels in Leukocytic DNA of Workers at a Chinese Asbestosmaterial Plant. Int. J. Occup. Environ. Health 1997, 3, 111-119.
-
(1997)
Int. J. Occup. Environ. Health.
, vol.3
, pp. 111-119
-
-
Takahashi, K.1
Pan, G.2
Kasai, H.3
Hanaoka, T.4
Feng, Y.5
Liu, N.6
Zhang, S.7
Xu, Z.8
Tsuda, T.9
Yamato, H.10
Higashi, T.11
Okubo, T.12
-
17
-
-
0034632209
-
Association between 8-hydroxy-2'-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer
-
Marczynski, B.; Kraus, T.; Rozynek, P.; Raithel, H.J.; Baur, X. Association between 8-hydroxy-2'-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer. Mutat. Res. 2000, 468, 203-212.
-
(2000)
Mutat. Res.
, vol.468
, pp. 203-212
-
-
Marczynski, B.1
Kraus, T.2
Rozynek, P.3
Raithel, H.J.4
Baur, X.5
-
18
-
-
66149088854
-
8-hydroxy-2'-deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis
-
Valavanidis, A.; Vlachogianni, T.; Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis. J. Environ. Sci. Health 2009, 27, 20-139.
-
(2009)
J. Environ. Sci. Health.
, vol.27
, pp. 20-139
-
-
Valavanidis, A.1
Vlachogianni, T.2
Fiotakis, C.3
-
19
-
-
0029760618
-
Relationship between the intracellular reactive oxygen species and the induction of oxidative DNA damage in human neutrophil-like cells
-
Takeuchi, T.; Nakajima, M.; Morimoto, K. Relationship between the intracellular reactive oxygen species and the induction of oxidative DNA damage in human neutrophil-like cells. Carcinogenesis 1996, 17, 1543-1548.
-
(1996)
Carcinogenesis
, vol.17
, pp. 1543-1548
-
-
Takeuchi, T.1
Nakajima, M.2
Morimoto, K.3
-
20
-
-
12944266921
-
A method for routine quntification of urinary 8-hydroxy-2'-deoxyguanosine based on solid-phase extraction and micro-highperformance liquid chromatography/electrospry ionization tandem mass spectrometry
-
Sabatini, L.; Barbieri, A.; Tosi, M.; Roda, A.; Violante, F.S. A method for routine quntification of urinary 8-hydroxy-2'-deoxyguanosine based on solid-phase extraction and micro-highperformance liquid chromatography/electrospry ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 147-152.
-
(2005)
Rapid Commun. Mass Spectrom.
, vol.19
, pp. 147-152
-
-
Sabatini, L.1
Barbieri, A.2
Tosi, M.3
Roda, A.4
Violante, F.S.5
-
21
-
-
0034916609
-
Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay
-
Collins, A.R.; Dusinská, M.; Horváthová, E.; Munro, E.; Savio, M.; Stetina, R. Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay. Mutagenesis 2001, 16, 297-301.
-
(2001)
Mutagenesis
, vol.16
, pp. 297-301
-
-
Collins, A.R.1
Dusinská, M.2
Horváthová, E.3
Munro, E.4
Savio, M.5
Stetina, R.6
-
22
-
-
0035378494
-
In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage
-
Tomasetti, M.; Alleva, R.; Borghi, B.; Collins, A.R. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J. 2001, 15, 1425-1427.
-
(2001)
FASEB J
, vol.15
, pp. 1425-1427
-
-
Tomasetti, M.1
Alleva, R.2
Borghi, B.3
Collins, A.R.4
-
23
-
-
69849093579
-
DNA damage in human spermatozoa is highly correlated with the efficiency of chromatin remodeling and the formation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress
-
De Iuliis, G.N.; Thomson, L.K.; Mitchell, L.A.; Finnie, J.M.; Koppers, A.J.; Hedges, A.; Nixon, B.; Aitken, R.J. DNA damage in human spermatozoa is highly correlated with the efficiency of chromatin remodeling and the formation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress. Biol. Reprod. 2009, 81, 517-524.
-
(2009)
Biol. Reprod.
, vol.81
, pp. 517-524
-
-
de Iuliis, G.N.1
Thomson, L.K.2
Mitchell, L.A.3
Finnie, J.M.4
Koppers, A.J.5
Hedges, A.6
Nixon, B.7
Aitken, R.J.8
-
24
-
-
38849095130
-
Profiling tumor-associated markers for early detection of malignant mesothelioma: An epidemiologic study
-
Amati, M.; Tomasetti, M.; Scartozzi, M.; Mariotti, L.; Alleva, R.; Pignotti, E.; Borghi, B.; Valentino, M.; Governa, M.; Neuzil, J.; Santarelli, L. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 163-170.
-
(2008)
Cancer Epidemiol. Biomarkers Prev.
, vol.17
, pp. 163-170
-
-
Amati, M.1
Tomasetti, M.2
Scartozzi, M.3
Mariotti, L.4
Alleva, R.5
Pignotti, E.6
Borghi, B.7
Valentino, M.8
Governa, M.9
Neuzil, J.10
Santarelli, L.11
-
25
-
-
58149291810
-
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk
-
Amati, M.; Tomasetti, M.; Mariotti, L.; Tarquini, L.M.; Valentino, M.; Santarelli, L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 2008, 655, 52-58.
-
(2008)
Mutat. Res.
, vol.655
, pp. 52-58
-
-
Amati, M.1
Tomasetti, M.2
Mariotti, L.3
Tarquini, L.M.4
Valentino, M.5
Santarelli, L.6
-
26
-
-
0035835437
-
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
-
Roushdy-Hammady, I.; Siegel, J.; Emri, S.; Testa, J.R.; Carbone, M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357, 444-445.
-
(2001)
Lancet
, vol.357
, pp. 444-445
-
-
Roushdy-Hammady, I.1
Siegel, J.2
Emri, S.3
Testa, J.R.4
Carbone, M.5
-
27
-
-
3342998510
-
Genotoxic effects of asbestos in humans
-
Dusinská, M.; Collins, A.; Kazimírová, A.; Barancoková, M.; Harrington, V.; Volkovová, K.; Staruchová, M.; Horská, A.; Wsólová, L.; Kocan, A.; Petrík, J.; Machata, M.; Ratcliffe, B.; Kyrtopoulos, S. Genotoxic effects of asbestos in humans. Mutat. Res. 2004, 553, 91-102.
-
(2004)
Mutat. Res.
, vol.553
, pp. 91-102
-
-
Dusinská, M.1
Collins, A.2
Kazimírová, A.3
Barancoková, M.4
Harrington, V.5
Volkovová, K.6
Staruchová, M.7
Horská, A.8
Wsólová, L.9
Kocan, A.10
Petrík, J.11
Machata, M.12
Ratcliffe, B.13
Kyrtopoulos, S.14
-
28
-
-
3342984893
-
Does occupational exposure to mineral fibres cause DNA or chromosome damage
-
Dusinská, M.; Barancoková, M.; Kazimírová, A.; Harrington, V.; Volkovová, K.; Staruchová, M.; Horská, A.; Wsólová, L.; Collins, A. Does occupational exposure to mineral fibres cause DNA or chromosome damage? Mutat. Res. 2004, 553, 103-110.
-
(2004)
Mutat. Res.
, vol.553
, pp. 103-110
-
-
Dusinská, M.1
Barancoková, M.2
Kazimírová, A.3
Harrington, V.4
Volkovová, K.5
Staruchová, M.6
Horská, A.7
Wsólová, L.8
Collins, A.9
-
29
-
-
0032520973
-
Impaired DNA repair as assessed by the comet assay in patients with thyroid tumors after a history of radiation therapy: A preliminary study
-
Leprat, F.; Alapetite, C.; Rosselli, F.; Ridet, A.; Schlumberger, M.; Sarasin, A.; Suarez, H.G.; Moustacchi, E. Impaired DNA repair as assessed by the comet assay in patients with thyroid tumors after a history of radiation therapy: a preliminary study. Int. J. Radiat. Oncol. Biol. Phys.1998, 40, 1019-1026.
-
(1998)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.40
, pp. 1019-1026
-
-
Leprat, F.1
Alapetite, C.2
Rosselli, F.3
Ridet, A.4
Schlumberger, M.5
Sarasin, A.6
Suarez, H.G.7
Moustacchi, E.8
-
30
-
-
0344624874
-
Bleomycininduced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay
-
Jaloszynski, P.; Kujawski, M.; Czub-Swierczek, M.; Markowska, J.; Szyfter, K. Bleomycininduced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay. Mutat. Res. 1997, 385, 223-233.
-
(1997)
Mutat. Res.
, vol.385
, pp. 223-233
-
-
Jaloszynski, P.1
Kujawski, M.2
Czub-Swierczek, M.3
Markowska, J.4
Szyfter, K.5
-
31
-
-
0035169329
-
Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes
-
Schmezer, P.; Rajaee-Behbahani, N.; Risch, A.; Thiel, S.; Rittgen, W.; Drings, P.; Dienemann, H.; Kayser, K.W.; Schulz, V.; Bartsch, H. Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis 2001, 16, 25-30.
-
(2001)
Mutagenesis
, vol.16
, pp. 25-30
-
-
Schmezer, P.1
Rajaee-Behbahani, N.2
Risch, A.3
Thiel, S.4
Rittgen, W.5
Drings, P.6
Dienemann, H.7
Kayser, K.W.8
Schulz, V.9
Bartsch, H.10
-
32
-
-
0034653699
-
Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health
-
Bonassi, S.; Hagmar, L.; Strömberg, U.; Montagud, A.H.; Tinnerberg, H.; Forni, A.; Heikkilä, P.; Wanders, S.; Wilhardt, P.; Hansteen, I.L.; Knudsen, L.E.; Norppa, H. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res. 2000, 60, 1619-1625.
-
(2000)
Cancer Res
, vol.60
, pp. 1619-1625
-
-
Bonassi, S.1
Hagmar, L.2
Strömberg, U.3
Montagud, A.H.4
Tinnerberg, H.5
Forni, A.6
Heikkilä, P.7
Wanders, S.8
Wilhardt, P.9
Hansteen, I.L.10
Knudsen, L.E.11
Norppa, H.12
-
33
-
-
19044387319
-
Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer
-
Rossner, P.; Boffetta, P.; Ceppi, M.; Bonassi, S.; Smerhovsky, Z.; Landa, K.; Juzova, D.; Srám, R.J. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environ. Health Perspect. 2005, 113, 517-520.
-
(2005)
Environ. Health Perspect.
, vol.113
, pp. 517-520
-
-
Rossner, P.1
Boffetta, P.2
Ceppi, M.3
Bonassi, S.4
Smerhovsky, Z.5
Landa, K.6
Juzova, D.7
Srám, R.J.8
-
34
-
-
0037139239
-
Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation
-
Trenz, K.; Rothfuss, A.; Schütz, P.; Speit, G. Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation. Mutat. Res. 2002, 500, 89-96.
-
(2002)
Mutat. Res.
, vol.500
, pp. 89-96
-
-
Trenz, K.1
Rothfuss, A.2
Schütz, P.3
Speit, G.4
-
35
-
-
0036790035
-
High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma
-
Bolognesi, C.; Filiberti, R.; Neri, M.; Perrone, E.; Landini, E.; Canessa, P.A.; Simonassi, C.; Cerrano, P.G.; Mutti, L.; Puntoni, R. High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. Cancer Res. 2002, 62, 5418-5419.
-
(2002)
Cancer Res
, vol.62
, pp. 5418-5419
-
-
Bolognesi, C.1
Filiberti, R.2
Neri, M.3
Perrone, E.4
Landini, E.5
Canessa, P.A.6
Simonassi, C.7
Cerrano, P.G.8
Mutti, L.9
Puntoni, R.10
-
36
-
-
0036175321
-
The pathogenesis of mesothelioma
-
Carbone, M.; Kratzke, R.A.; Testa, J.R. The pathogenesis of mesothelioma. Semin. Oncol. 2002, 29, 2-17.
-
(2002)
Semin. Oncol.
, vol.29
, pp. 2-17
-
-
Carbone, M.1
Kratzke, R.A.2
Testa, J.R.3
-
37
-
-
0035201539
-
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effutions
-
Alatas, F.; Alatas, O.; Metintas, M.; Golak, O.; Harmanci, E.; Demir, S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effutions. Lung Cancer 2001, 31, 9-16.
-
(2001)
Lung Cancer
, vol.31
, pp. 9-16
-
-
Alatas, F.1
Alatas, O.2
Metintas, M.3
Golak, O.4
Harmanci, E.5
Demir, S.6
-
38
-
-
0034919372
-
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma
-
Paganuzzi, M.; Onetto, M.; Marroni, P.; Filiberti, R.; Tassara, E.; Parodi, S.; Felletti, R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001, 119, 1138-1142.
-
(2001)
Chest
, vol.119
, pp. 1138-1142
-
-
Paganuzzi, M.1
Onetto, M.2
Marroni, P.3
Filiberti, R.4
Tassara, E.5
Parodi, S.6
Felletti, R.7
-
39
-
-
65749101166
-
Clinical utility of diagnostic markers for malignant pleural mesothelioma
-
Grigoriu, B.D.; Grigoriu, C.; Chahine, B.; Gey, T.; Scherpereel, A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch. Chest Dis. 2009, 71, 31-38.
-
(2009)
Monaldi Arch. Chest Dis.
, vol.71
, pp. 31-38
-
-
Grigoriu, B.D.1
Grigoriu, C.2
Chahine, B.3
Gey, T.4
Scherpereel, A.5
-
40
-
-
40249113315
-
Non-invasive diagnosis of pleural malignancies: The role of tumour markers
-
van den Heuvel, M.M.; Korse, C.M.; Bonfrer, J.M.; Baas, P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008, 59, 350-354.
-
(2008)
Lung Cancer
, vol.59
, pp. 350-354
-
-
van den Heuvel, M.M.1
Korse, C.M.2
Bonfrer, J.M.3
Baas, P.4
-
41
-
-
0030817665
-
Cyfra 21-1 and TPA as markers in malignant mesothelioma
-
Bonfrer, J.M.; Schouwink, J.H.; Korse, C.M.; Baas, P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res. 1997, 17, 2971-2973.
-
(1997)
Anticancer Res
, vol.17
, pp. 2971-2973
-
-
Bonfrer, J.M.1
Schouwink, J.H.2
Korse, C.M.3
Baas, P.4
-
42
-
-
0031983201
-
Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions
-
Salama, G.; Miédougé, M.; Rouzaud, P.; Mauduyt, M.A.; Pujazon, M.C.; Vincent, C.; Carles, P.; Serre, G. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br. J. Cancer 1998, 77, 472-476.
-
(1998)
Br. J. Cancer.
, vol.77
, pp. 472-476
-
-
Salama, G.1
Miédougé, M.2
Rouzaud, P.3
Mauduyt, M.A.4
Pujazon, M.C.5
Vincent, C.6
Carles, P.7
Serre, G.8
-
43
-
-
0030045417
-
CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions
-
Romero, S.; Fernández, C.; Arriero, J.M.; Espasa, A.; Candela, A.; Martín, C.; Sánchez-Payá, J. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur. Respir. J. 1996, 9, 17-23.
-
(1996)
Eur. Respir. J.
, vol.9
, pp. 17-23
-
-
Romero, S.1
Fernández, C.2
Arriero, J.M.3
Espasa, A.4
Candela, A.5
Martín, C.6
Sánchez-Payá, J.7
-
44
-
-
10444263784
-
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions
-
Porcel, J.M.; Vives, M.; Esquerda, A.; Salud, A.; Pérez, B.; Rodríguez-Panadero, F.Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004, 126, 1757-1763.
-
(2004)
Chest
, vol.126
, pp. 1757-1763
-
-
Porcel, J.M.1
Vives, M.2
Esquerda, A.3
Salud, A.4
Pérez, B.5
Rodríguez-Panadero, F.6
-
45
-
-
0023792142
-
Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma
-
Pettersson, T.; Fröseth, B.; Riska, H.; Klockars, M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988, 94, 1037-1039.
-
(1988)
Chest
, vol.94
, pp. 1037-1039
-
-
Pettersson, T.1
Fröseth, B.2
Riska, H.3
Klockars, M.4
-
46
-
-
0031253106
-
Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: Likelihood ratios for malignant mesothelioma
-
Atagi, S.; Ogawara, M.; Kawahara, M.; Sakatani, M.; Furuse, K.; Ueda, E.; Yamamoto, S. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn. J. Clin. Oncol. 1997, 27, 293-297.
-
(1997)
Jpn. J. Clin. Oncol.
, vol.27
, pp. 293-297
-
-
Atagi, S.1
Ogawara, M.2
Kawahara, M.3
Sakatani, M.4
Furuse, K.5
Ueda, E.6
Yamamoto, S.7
-
47
-
-
67349283784
-
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma
-
Grigoriu, B.; Chahine, B.; Zerimech, F.; Grégoire, M.; Balduyck, M.; Copin, M.C.; Devos, P.; Lassalle, P.; Scherpereel, A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin. Biochem. 2009, 42, 1046-1050.
-
(2009)
Clin. Biochem.
, vol.42
, pp. 1046-1050
-
-
Grigoriu, B.1
Chahine, B.2
Zerimech, F.3
Grégoire, M.4
Balduyck, M.5
Copin, M.C.6
Devos, P.7
Lassalle, P.8
Scherpereel, A.9
-
48
-
-
26444506232
-
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
-
Pass, H.I.; Lott, D.; Lonardo, F.; Harbut, M.; Liu, Z.; Tang, N.; Carbone, M.; Webb, C.; Wali, A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005, 353, 1564-1573.
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 1564-1573
-
-
Pass, H.I.1
Lott, D.2
Lonardo, F.3
Harbut, M.4
Liu, Z.5
Tang, N.6
Carbone, M.7
Webb, C.8
Wali, A.9
-
49
-
-
26444521661
-
Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma
-
Cullen, M.R. Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma? N. Engl. J. Med. 2005, 353, 1617-1618.
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 1617-1618
-
-
Cullen, M.R.1
-
50
-
-
6344258588
-
The role of Osteopontin in tumor metastasis
-
Wai, P.Y.; Kuo, P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res. 2004, 121, 228-241.
-
(2004)
J. Surg. Res.
, vol.121
, pp. 228-241
-
-
Wai, P.Y.1
Kuo, P.C.2
-
51
-
-
63149105992
-
Osteopontin levels in an asbestos-exposed population
-
Park, E.K.; Thomas, P.S.; Johnson, A.R.; Yates, D.H. Osteopontin levels in an asbestos-exposed population. Clin. Cancer Res. 2009, 15, 1362-1366.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 1362-1366
-
-
Park, E.K.1
Thomas, P.S.2
Johnson, A.R.3
Yates, D.H.4
-
52
-
-
34249781709
-
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
-
Grigoriu, B.D.; Scherpereel, A.; Devos, P.; Chahine, B.; Letourneux, M.; Lebailly, P.; Grégoire, M.; Porte, H.; Copin, M.C.; Lassalle, P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13, 2928-2935.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 2928-2935
-
-
Grigoriu, B.D.1
Scherpereel, A.2
Devos, P.3
Chahine, B.4
Letourneux, M.5
Lebailly, P.6
Grégoire, M.7
Porte, H.8
Copin, M.C.9
Lassalle, P.10
-
53
-
-
49649095966
-
Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites
-
Myles, T.; Leung, L.L. Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J. Biol. Chem. 2008, 283, 17789-17796.
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 17789-17796
-
-
Myles, T.1
Leung, L.L.2
-
54
-
-
35648934023
-
Control of osteopontin signaling and function by post-translational phosphorylation and protein folding
-
Kazanecki, C.C.; Uzwiak, D.J.; Denhardt, D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell Biochem. 2007, 102, 912-24.
-
(2007)
J. Cell Biochem.
, vol.102
, pp. 912-924
-
-
Kazanecki, C.C.1
Uzwiak, D.J.2
Denhardt, D.T.3
-
55
-
-
70349768829
-
Osteopontin is not a specific marker in malignant pleural mesothelioma
-
Paleari, L.; Rotolo, N.; Imperatori, A.; Puzone, R.; Sessa, F.; Franzi, F.; Meacci, E.; Camplese, P.; Cesario, A.; Paganizzi, M. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int. J. Biol. Markers. 2009, 24, 112-117.
-
(2009)
Int. J. Biol. Markers.
, vol.24
, pp. 112-117
-
-
Paleari, L.1
Rotolo, N.2
Imperatori, A.3
Puzone, R.4
Sessa, F.5
Franzi, F.6
Meacci, E.7
Camplese, P.8
Cesario, A.9
Paganizzi, M.10
-
56
-
-
0035671826
-
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer
-
Fedarko, N.S.; Jain, A.; Karadag, A.; Van Eman, M.R.; Fisher, L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 2001, 7, 4060-4066.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 4060-4066
-
-
Fedarko, N.S.1
Jain, A.2
Karadag, A.3
van Eman, M.R.4
Fisher, L.W.5
-
57
-
-
2642676024
-
Co-expression of osteopontin and CD44v9 in gastric cancer
-
Ue, T.; Yokozaki, H.; Kitadai, Y.; Yamamoto, S.; Yasui, W.; Ishikawa, T.; Tahara, E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer. 1998, 79, 127-132.
-
(1998)
Int. J. Cancer.
, vol.79
, pp. 127-132
-
-
Ue, T.1
Yokozaki, H.2
Kitadai, Y.3
Yamamoto, S.4
Yasui, W.5
Ishikawa, T.6
Tahara, E.7
-
58
-
-
42649088733
-
Overexpression of osteopontin in clear cell carcinoma of the ovary: Close association with HNF-1beta expression
-
Kato, N.; Motoyama, T. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 2008, 52, 682-688.
-
(2008)
Histopathology
, vol.52
, pp. 682-688
-
-
Kato, N.1
Motoyama, T.2
-
59
-
-
20944443085
-
Osteopontin expression correlates with melanoma invasion
-
Zhou, Y.; Dai, D.L., Martinka, M.; Su, M.; Zhang, Y.; Campos, E.I.; Dorocicz, I.; Tang, L.; Huntsman, D.; Nelson, C.; Ho, V.; Li, G. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 2005, 124, 1044-1052.
-
(2005)
J. Invest. Dermatol.
, vol.124
, pp. 1044-1052
-
-
Zhou, Y.1
Dai, D.L.2
Martinka, M.3
Su, M.4
Zhang, Y.5
Campos, E.I.6
Dorocicz, I.7
Tang, L.8
Huntsman, D.9
Nelson, C.10
Ho, V.11
Li, G.12
-
60
-
-
0344851540
-
Mesothelin-family proteins and diagnosis of mesothelioma
-
Robinson, B.W.; Creaney, J.; Lake, R.; Nowak, A.; Musk, A.W.; de Klerk, N.; Winzell, P.; Hellstrom, K.E.; Hellstrom, I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362, 1612-1616.
-
(2003)
Lancet
, vol.362
, pp. 1612-1616
-
-
Robinson, B.W.1
Creaney, J.2
Lake, R.3
Nowak, A.4
Musk, A.W.5
de Klerk, N.6
Winzell, P.7
Hellstrom, K.E.8
Hellstrom, I.9
-
61
-
-
33646587019
-
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma
-
Scherpereel, A.; Grigoriu, B.; Conti, M.; Gey, T.; Grégoire, M.; Copin, M.C.; Devos, P.; Chahine, B.; Porte, H.; Lassalle, P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173, 1155-1160.
-
(2006)
Am. J. Respir. Crit. Care Med.
, vol.173
, pp. 1155-1160
-
-
Scherpereel, A.1
Grigoriu, B.2
Conti, M.3
Gey, T.4
Grégoire, M.5
Copin, M.C.6
Devos, P.7
Chahine, B.8
Porte, H.9
Lassalle, P.10
-
62
-
-
74049130251
-
Designing early detection programs for ovarian cancer
-
Hartge, P. Designing early detection programs for ovarian cancer. J. Natl. Cancer Inst. 2010, 102, 3-4.
-
(2010)
J. Natl. Cancer Inst.
, vol.102
, pp. 3-4
-
-
Hartge, P.1
-
63
-
-
70350714432
-
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer
-
Johnston, F.M.; Tan, M.C.; Tan, B.R. Jr.; Porembka, M.R.; Brunt, E.M.; Linehan, D.C.; Simon, P.O., Jr.; Plambeck-Suess, S.; Eberlein, T.J.; Hellstrom, K.E.; Hellstrom, I.; Hawkins, W.G.; Goedegebuure, P. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin. Cancer Res. 2009, 15, 6511-6518.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 6511-6518
-
-
Johnston, F.M.1
Tan, M.C.2
Tan Jr., B.R.3
Porembka, M.R.4
Brunt, E.M.5
Linehan, D.C.6
Simon Jr., P.O.7
Plambeck-Suess, S.8
Eberlein, T.J.9
Hellstrom, K.E.10
Hellstrom, I.11
Hawkins, W.G.12
Goedegebuure, P.13
-
64
-
-
31544439933
-
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
-
Hassan, R.; Remaley, A.T.; Sampson, M.L.; Zhang, J.; Cox, D.D.; Pingpank, J.; Alexander, R.; Willingham, M.; Pastan, I.; Onda, M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12, 447-453.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 447-453
-
-
Hassan, R.1
Remaley, A.T.2
Sampson, M.L.3
Zhang, J.4
Cox, D.D.5
Pingpank, J.6
Alexander, R.7
Willingham, M.8
Pastan, I.9
Onda, M.10
-
65
-
-
60549101347
-
Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestosrelated pleural disease: Relation with past asbestos exposure
-
Rodríguez Portal, J.A.; Rodríguez Becerra, E.; Rodríguez Rodríguez, D.; Alfageme Michavila, I.; Quero Martínez, A.; Diego Roza, C.; León Jiménez, A.; Isidro Montes, I.; Cebollero Rivas, P. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestosrelated pleural disease: relation with past asbestos exposure. Cancer Epidemiol. Biomarkers Prev.2009, 18, 646-650.
-
(2009)
Cancer Epidemiol. Biomarkers Prev.
, vol.18
, pp. 646-650
-
-
Rodríguez Portal, J.A.1
Rodríguez Becerra, E.2
Rodríguez Rodríguez, D.3
Alfageme Michavila, I.4
Quero Martínez, A.5
Diego Roza, C.6
León Jiménez, A.7
Isidro Montes, I.8
Cebollero Rivas, P.9
-
66
-
-
52149108100
-
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin
-
Iwahori, K.; Osaki, T.; Serada, S.; Fujimoto, M.; Suzuki, H.; Kishi, Y.; Yokoyama, A.; Hamada, H.; Fujii, Y.; Yamaguchi, K.; Hirashima, T.; Matsui, K.; Tachibana, I.; Nakamura, Y.; Kawase, I.; Naka, T. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008, 62, 45-54.
-
(2008)
Lung Cancer
, vol.62
, pp. 45-54
-
-
Iwahori, K.1
Osaki, T.2
Serada, S.3
Fujimoto, M.4
Suzuki, H.5
Kishi, Y.6
Yokoyama, A.7
Hamada, H.8
Fujii, Y.9
Yamaguchi, K.10
Hirashima, T.11
Matsui, K.12
Tachibana, I.13
Nakamura, Y.14
Kawase, I.15
Naka, T.16
-
67
-
-
34147195762
-
MESOMARK: A potential test for malignant pleural mesothelioma
-
Beyer, H.L.; Geschwindt, R.D.; Glover, C.L.; Tran, L.; Hellstrom, I.; Hellstrom, K.E.; Miller, M.C.; Verch, T.; Allard, W.J.; Pass, H.I.; Sardesai, N.Y. MESOMARK: a potential test for malignant pleural mesothelioma. Clin. Chem. 2007, 53, 666-672.
-
(2007)
Clin. Chem.
, vol.53
, pp. 666-672
-
-
Beyer, H.L.1
Geschwindt, R.D.2
Glover, C.L.3
Tran, L.4
Hellstrom, I.5
Hellstrom, K.E.6
Miller, M.C.7
Verch, T.8
Allard, W.J.9
Pass, H.I.10
Sardesai, N.Y.11
-
68
-
-
34548822434
-
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
-
Cristaudo, A.; Foddis, R.; Vivaldi, A.; Guglielmi, G.; Dipalma, N.; Filiberti, R.; Neri, M.; Ceppi, M.; Paganuzzi, M.; Ivaldi, G.P.; Mencoboni, M.; Canessa, P.A.; Ambrosino, N.; Chella, A.; Mutti, L.; Puntoni, R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 2007, 13, 5076-5081.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 5076-5081
-
-
Cristaudo, A.1
Foddis, R.2
Vivaldi, A.3
Guglielmi, G.4
Dipalma, N.5
Filiberti, R.6
Neri, M.7
Ceppi, M.8
Paganuzzi, M.9
Ivaldi, G.P.10
Mencoboni, M.11
Canessa, P.A.12
Ambrosino, N.13
Chella, A.14
Mutti, L.15
Puntoni, R.16
-
69
-
-
54049102427
-
Soluble mesothelin-related protein in an asbestos-exposed population: The dust diseases board cohort study
-
Park, E.K.; Sandrini, A.; Yates, D.H.; Creaney, J.; Robinson, B.W.; Thomas, P.S.; Johnson, A.R. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008, 178, 832-837.
-
(2008)
Am. J. Respir. Crit. Care Med.
, vol.178
, pp. 832-837
-
-
Park, E.K.1
Sandrini, A.2
Yates, D.H.3
Creaney, J.4
Robinson, B.W.5
Thomas, P.S.6
Johnson, A.R.7
-
70
-
-
58149291810
-
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk
-
Amati, M.; Tomasetti, M.; Mariotti, L.; Tarquini, L.M.; Valentino, M.; Santarelli, L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 2008, 655, 52-58.
-
(2008)
Mutat. Res.
, vol.655
, pp. 52-58
-
-
Amati, M.1
Tomasetti, M.2
Mariotti, L.3
Tarquini, L.M.4
Valentino, M.5
Santarelli, L.6
-
71
-
-
73749086059
-
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis
-
Luo, L.; Shi, H.Z.; Liang, Q.L.; Jiang, J.; Qin, S.M.; Deng, J.M. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis. Respir. Med. 2010, 104, 149-156.
-
(2010)
Respir. Med.
, vol.104
, pp. 149-156
-
-
Luo, L.1
Shi, H.Z.2
Liang, Q.L.3
Jiang, J.4
Qin, S.M.5
Deng, J.M.6
-
72
-
-
33746624342
-
Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients
-
Shiomi, K.; Miyamoto, H.; Segawa, T.; Hagiwara, Y.; Ota, A.; Maeda, M.; Takahashi, K.; Masuda, K.; Sakao, Y.; Hino, O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006, 97, 928-932.
-
(2006)
Cancer Sci
, vol.97
, pp. 928-932
-
-
Shiomi, K.1
Miyamoto, H.2
Segawa, T.3
Hagiwara, Y.4
Ota, A.5
Maeda, M.6
Takahashi, K.7
Masuda, K.8
Sakao, Y.9
Hino, O.10
-
73
-
-
33749998312
-
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma
-
Onda, M.; Nagata, S.; Ho, M.; Bera, T.K.; Hassan, R.; Alexander, R.H.; Pastan, I. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res. 2006, 12, 4225-4231.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 4225-4231
-
-
Onda, M.1
Nagata, S.2
Ho, M.3
Bera, T.K.4
Hassan, R.5
Alexander, R.H.6
Pastan, I.7
-
74
-
-
57349191952
-
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma
-
Creaney, J.; Yeoman, D.; Demelker, Y.; Segal, A.; Musk, A.W.; Skates, S.J.; Robinson, B.W. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 2008, 3, 851-857.
-
(2008)
J. Thorac. Oncol.
, vol.3
, pp. 851-857
-
-
Creaney, J.1
Yeoman, D.2
Demelker, Y.3
Segal, A.4
Musk, A.W.5
Skates, S.J.6
Robinson, B.W.7
-
75
-
-
77749307355
-
Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma
-
Hollevoet, K.; Nackaerts, K.; Thimpont, J.; Germonpré, P.; Bosquée, L.; De Vuyst, P.; Legrand, C.; Kellen, E.; Kishi, Y.; Delanghe, J.R.; van Meerbeeck, J.P. Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. Am. J. Respir. Crit. Care Med. 2010, 181, 620-625.
-
(2010)
Am. J. Respir. Crit. Care Med.
, vol.181
, pp. 620-625
-
-
Hollevoet, K.1
Nackaerts, K.2
Thimpont, J.3
Germonpré, P.4
Bosquée, L.5
de Vuyst, P.6
Legrand, C.7
Kellen, E.8
Kishi, Y.9
Delanghe, J.R.10
van Meerbeeck, J.P.11
-
76
-
-
24644454772
-
Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: Analysis of 116 cases and review of the literature
-
Shitrit, D.; Zingerman, B.; Shitrit, A.B.; Shlomi, D.; Kramer, M.R. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005, 10, 501-507.
-
(2005)
Oncologist
, vol.10
, pp. 501-507
-
-
Shitrit, D.1
Zingerman, B.2
Shitrit, A.B.3
Shlomi, D.4
Kramer, M.R.5
-
77
-
-
35448975176
-
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma
-
Creaney, J.; van Bruggen, I.; Hof, M.; Segal, A.; Musk, A.W.; de Klerk, N.; Horick, N.; Skates, S.J.; Robinson, B.W. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132, 1239-1246.
-
(2007)
Chest
, vol.132
, pp. 1239-1246
-
-
Creaney, J.1
van Bruggen, I.2
Hof, M.3
Segal, A.4
Musk, A.W.5
de Klerk, N.6
Horick, N.7
Skates, S.J.8
Robinson, B.W.9
-
78
-
-
0036274359
-
The fundamental role of epigenetic events in cancer
-
Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.2002, 3, 415-428.
-
(2002)
Nat. Rev. Genet.
, vol.3
, pp. 415-428
-
-
Jones, P.A.1
Baylin, S.B.2
-
79
-
-
71549131914
-
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma
-
Goto, Y.; Shinjo, K.; Kondo, Y.; Shen, L.; Toyota, M.; Suzuki, H.; Gao, W.; An, B.; Fujii, M.; Murakami, H.; Osada, H.; Taniguchi, T.; Usami, N.; Kondo, M.; Hasegawa, Y.; Shimokata, K.; Matsuo, K.; Hida, T.; Fujimoto, N.; Kishimoto, T.; Issa, J.P.; Sekido, Y. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009, 69, 9073-9082.
-
(2009)
Cancer Res
, vol.69
, pp. 9073-9082
-
-
Goto, Y.1
Shinjo, K.2
Kondo, Y.3
Shen, L.4
Toyota, M.5
Suzuki, H.6
Gao, W.7
An, B.8
Fujii, M.9
Murakami, H.10
Osada, H.11
Taniguchi, T.12
Usami, N.13
Kondo, M.14
Hasegawa, Y.15
Shimokata, K.16
Matsuo, K.17
Hida, T.18
Fujimoto, N.19
Kishimoto, T.20
Issa, J.P.21
Sekido, Y.22
more..
-
80
-
-
35648983903
-
Inflammation and cancer: An ancient link with novel potentials
-
Hussain, S.P.; Harris, C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121, 2373-2380.
-
(2007)
Int. J. Cancer.
, vol.121
, pp. 2373-2380
-
-
Hussain, S.P.1
Harris, C.C.2
-
81
-
-
19944429818
-
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung
-
Tsou, J.A.; Shen, L.Y.; Siegmund, K.D.; Long, T.I.; Laird, P.W.; Seneviratne, C.K.; Koss, M.N.; Pass, H.I.; Hagen, J.A.; Laird-Offringa, I.A. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005, 47, 193-204.
-
(2005)
Lung Cancer
, vol.47
, pp. 193-204
-
-
Tsou, J.A.1
Shen, L.Y.2
Siegmund, K.D.3
Long, T.I.4
Laird, P.W.5
Seneviratne, C.K.6
Koss, M.N.7
Pass, H.I.8
Hagen, J.A.9
Laird-Offringa, I.A.10
-
82
-
-
34848873175
-
DNA methylation profile of 28 potential marker loci in malignant mesothelioma
-
Tsou, J.A.; Galler, J.S.; Wali, A.; Ye, W.; Siegmund, K.D.; Groshen, S.; Laird, P.W.; Turla, S.; Koss, M.N.; Pass, H.I.; Laird-Offringa, I.A.DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007, 58, 220-230.
-
(2007)
Lung Cancer
, vol.58
, pp. 220-230
-
-
Tsou, J.A.1
Galler, J.S.2
Wali, A.3
Ye, W.4
Siegmund, K.D.5
Groshen, S.6
Laird, P.W.7
Turla, S.8
Koss, M.N.9
Pass, H.I.10
Laird-Offringa, I.A.11
-
83
-
-
33745892099
-
TNF-alpha inhibits asbestosinduced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestosinduced oncogenesis
-
Yang, H.; Bocchetta, M.; Kroczynska, B.; Elmishad, A.G.; Chen, Y.; Liu, Z.; Bubici, C.; Mossman, B.T.; Pass, H.I.; Testa, J.R.; Franzoso, G.; Carbone, M. TNF-alpha inhibits asbestosinduced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestosinduced oncogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 10397-10402.
-
(2006)
Proc. Natl. Acad. Sci. USA.
, vol.103
, pp. 10397-10402
-
-
Yang, H.1
Bocchetta, M.2
Kroczynska, B.3
Elmishad, A.G.4
Chen, Y.5
Liu, Z.6
Bubici, C.7
Mossman, B.T.8
Pass, H.I.9
Testa, J.R.10
Franzoso, G.11
Carbone, M.12
-
84
-
-
0020581141
-
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
-
Shapiro, B.; Chakrabarty, M.; Cohn, E.M.; Leon, S.A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983, 51, 2116-2120.
-
(1983)
Cancer
, vol.51
, pp. 2116-2120
-
-
Shapiro, B.1
Chakrabarty, M.2
Cohn, E.M.3
Leon, S.A.4
-
85
-
-
33846258311
-
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma
-
Fischer, J.R.; Ohnmacht, U.; Rieger, N.; Zemaitis, M.; Stoffregen, C.; Kostrzewa, M.; Buchholz, E.; Manegold, C.; Lahm, H. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54, 109-116.
-
(2006)
Lung Cancer
, vol.54
, pp. 109-116
-
-
Fischer, J.R.1
Ohnmacht, U.2
Rieger, N.3
Zemaitis, M.4
Stoffregen, C.5
Kostrzewa, M.6
Buchholz, E.7
Manegold, C.8
Lahm, H.9
-
86
-
-
77955590791
-
MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer
-
Doi: 10.1002/ijc.25162
-
Rauhala, H.E., Jalava, S.E.; Isotalo, J.; Bracken, H.; Lehmusvaara, S.; Tammela, T.L.; Oja, H.; Visakorpi, T. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer 2010, Doi: 10.1002/ijc.25162.
-
(2010)
Int. J. Cancer.
-
-
Rauhala, H.E.1
Jalava, S.E.2
Isotalo, J.3
Bracken, H.4
Lehmusvaara, S.5
Tammela, T.L.6
Oja, H.7
Visakorpi, T.8
-
87
-
-
49749126791
-
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
-
Lodygin, D.; Tarasov, V.; Epanchintsev, A.; Berking, C.; Knyazeva, T.; Körner, H.; Knyazev, P.; Diebold, J.; Hermeking, H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7, 2591-2600.
-
(2008)
Cell Cycle
, vol.7
, pp. 2591-2600
-
-
Lodygin, D.1
Tarasov, V.2
Epanchintsev, A.3
Berking, C.4
Knyazeva, T.5
Körner, H.6
Knyazev, P.7
Diebold, J.8
Hermeking, H.9
-
88
-
-
33846462025
-
-
Wijnhoven, B.P.; Michael, M.Z.; Watson, D.I. MicroRNAs and cancer. Br. J. Surg. 2007, 94, 23-30.
-
(2007)
MicroRNAs and Cancer. Br. J. Surg.
, vol.94
, pp. 23-30
-
-
Wijnhoven, B.P.1
Michael, M.Z.2
Watson, D.I.3
-
89
-
-
70349320158
-
Causes and consequences of microRNA dysregulation in cancer
-
Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet.2009, 10, 704-714.
-
(2009)
Nat. Rev. Genet.
, vol.10
, pp. 704-714
-
-
Croce, C.M.1
-
90
-
-
33750370444
-
MicroRNA signatures in human cancers
-
Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
-
(2006)
Nat. Rev. Cancer.
, vol.6
, pp. 857-866
-
-
Calin, G.A.1
Croce, C.M.2
-
91
-
-
20444460289
-
MicroRNA expression profiles classify human cancers
-
Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; Downing, J.R.; Jacks, T.; Horvitz, H.R.; Golub, T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
-
(2005)
Nature
, vol.435
, pp. 834-838
-
-
Lu, J.1
Getz, G.2
Miska, E.A.3
Alvarez-Saavedra, E.4
Lamb, J.5
Peck, D.6
Sweet-Cordero, A.7
Ebert, B.L.8
Mak, R.H.9
Ferrando, A.A.10
Downing, J.R.11
Jacks, T.12
Horvitz, H.R.13
Golub, T.R.14
-
92
-
-
34547807676
-
MiRNAs in cancer: Approaches, aetiology, diagnostics and therapy
-
Blenkiron, C.; Miska, E.A. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum. Mol. Genet. 2007, 16, R106-R113.
-
(2007)
Hum. Mol. Genet.
, vol.16
-
-
Blenkiron, C.1
Miska, E.A.2
-
93
-
-
67449086733
-
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis
-
Guled, M.; Lahti, L.; Lindholm, P.M.; Salmenkivi, K.; Bagwan, I.; Nicholson, A.G.; Knuutila, S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Gene. Chromosome. Canc. 2009, 48, 615-623.
-
(2009)
Gene. Chromosome. Canc.
, vol.48
, pp. 615-623
-
-
Guled, M.1
Lahti, L.2
Lindholm, P.M.3
Salmenkivi, K.4
Bagwan, I.5
Nicholson, A.G.6
Knuutila, S.7
-
94
-
-
77249135944
-
MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications
-
Busacca, S.; Germano, S.; De Cecco, L.; Rinaldi, M.; Comoglio, F.; Favero, F.; Murer, B.; Mutti, L.; Pierotti, M.; Gaudino, G. MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. Am. J. Respir. Cell Mol. Biol. 2010, 42, 312-319.
-
(2010)
Am. J. Respir. Cell Mol. Biol.
, vol.42
, pp. 312-319
-
-
Busacca, S.1
Germano, S.2
de Cecco, L.3
Rinaldi, M.4
Comoglio, F.5
Favero, F.6
Murer, B.7
Mutti, L.8
Pierotti, M.9
Gaudino, G.10
-
95
-
-
48749122914
-
Circulating microRNAs as stable blood-based markers for cancer detection
-
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
-
(2008)
Proc. Natl. Acad. Sci. USA.
, vol.105
, pp. 10513-10518
-
-
Mitchell, P.S.1
Parkin, R.K.2
Kroh, E.M.3
Fritz, B.R.4
Wyman, S.K.5
Pogosova-Agadjanyan, E.L.6
Peterson, A.7
Noteboom, J.8
O'Briant, K.C.9
Allen, A.10
Lin, D.W.11
Urban, N.12
Drescher, C.W.13
Knudsen, B.S.14
Stirewalt, D.L.15
Gentleman, R.16
Vessella, R.L.17
Nelson, P.S.18
Martin, D.B.19
Tewari, M.20
more..
-
96
-
-
63149121152
-
Circulating microRNAs, potential biomarkers for drug-induced liver injury
-
Wang, K.; Zhang, S.; Marzolf, B.; Troisch, P.; Brightman, A.; Hu, Z.; Hood, L.E.; Galas, D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci USA 2009, 106, 4402-4407.
-
(2009)
Proc. Natl. Acad. Sci USA.
, vol.106
, pp. 4402-4407
-
-
Wang, K.1
Zhang, S.2
Marzolf, B.3
Troisch, P.4
Brightman, A.5
Hu, Z.6
Hood, L.E.7
Galas, D.J.8
-
97
-
-
70349277287
-
Global gene expression profiling of human pleural mesotheliomas: Identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target
-
Crispi, S.; Calogero, R.A.; Santini, M.; Mellone, P.; Vincenzi, B.; Citro, G.; Vicidomini, G.; Fasano, S.; Meccariello, R.; Cobellis, G.; Menegozzo, S.; Pierantoni, R.; Facciolo, F.; Baldi, A.; Menegozzo, M. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009, 4, e7016.
-
(2009)
PLoS One
, vol.4
-
-
Crispi, S.1
Calogero, R.A.2
Santini, M.3
Mellone, P.4
Vincenzi, B.5
Citro, G.6
Vicidomini, G.7
Fasano, S.8
Meccariello, R.9
Cobellis, G.10
Menegozzo, S.11
Pierantoni, R.12
Facciolo, F.13
Baldi, A.14
Menegozzo, M.15
-
98
-
-
71549141637
-
Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets
-
Røe, O.D.; Anderssen, E.; Sandeck, H.; Christensen, T.; Larsson, E.; Lundgren, S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2010, 67, 57-68.
-
(2010)
Lung Cancer
, vol.67
, pp. 57-68
-
-
Røe, O.D.1
Anderssen, E.2
Sandeck, H.3
Christensen, T.4
Larsson, E.5
Lundgren, S.6
-
99
-
-
20444366275
-
Validation of genomics-based prognostic tests in malignant pleural mesothelioma
-
Gordon, G.J.; Rockwell, G.N.; Godfrey, P.A.; Jensen, R.V.; Glickman, J.N.; Yeap, B.Y.; Richards, W.G.; Sugarbaker, D.J.; Bueno, R. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 2005, 11, 4406-4414.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 4406-4414
-
-
Gordon, G.J.1
Rockwell, G.N.2
Godfrey, P.A.3
Jensen, R.V.4
Glickman, J.N.5
Yeap, B.Y.6
Richards, W.G.7
Sugarbaker, D.J.8
Bueno, R.9
-
100
-
-
10744226290
-
Gene expression profiles predict survival and progression of pleural mesothelioma
-
Pass, H.I.; Liu, Z.; Wali, A.; Bueno, R.; Land, S.; Lott, D.; Siddiq, F.; Lonardo, F.; Carbone, M.; Draghici, S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 2004, 10, 849-859.
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 849-859
-
-
Pass, H.I.1
Liu, Z.2
Wali, A.3
Bueno, R.4
Land, S.5
Lott, D.6
Siddiq, F.7
Lonardo, F.8
Carbone, M.9
Draghici, S.10
-
101
-
-
65549156408
-
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma
-
Gordon, G.J.; Dong, L.; Yeap, B.Y.; Richards, W.G.; Glickman, J.N.; Edenfield, H.; Mani, M.; Colquitt, R.; Maulik, G.; Van Oss, B.; Sugarbaker, D.J.; Bueno, R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl. Cancer Inst. 2009, 101, 678-686.
-
(2009)
J. Natl. Cancer Inst.
, vol.101
, pp. 678-686
-
-
Gordon, G.J.1
Dong, L.2
Yeap, B.Y.3
Richards, W.G.4
Glickman, J.N.5
Edenfield, H.6
Mani, M.7
Colquitt, R.8
Maulik, G.9
van Oss, B.10
Sugarbaker, D.J.11
Bueno, R.12
-
102
-
-
0032784551
-
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma
-
Schouwink, H.; Korse, C.M.; Bonfrer, J.M.; Hart, A.A.; Baas, P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999, 25, 25-32.
-
(1999)
Lung Cancer
, vol.25
, pp. 25-32
-
-
Schouwink, H.1
Korse, C.M.2
Bonfrer, J.M.3
Hart, A.A.4
Baas, P.5
-
103
-
-
0037233593
-
Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma
-
Hedman, M.; Arnberg, H.; Wernlund, J.; Riska, H.; Brodin, O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003, 23, 531-536.
-
(2003)
Anticancer Res
, vol.23
, pp. 531-536
-
-
Hedman, M.1
Arnberg, H.2
Wernlund, J.3
Riska, H.4
Brodin, O.5
-
104
-
-
0035447246
-
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma
-
Thylén, A.; Hjerpe, A.; Martensson, G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001, 92, 1224-1230.
-
(2001)
Cancer
, vol.92
, pp. 1224-1230
-
-
Thylén, A.1
Hjerpe, A.2
Martensson, G.3
-
105
-
-
24144456982
-
Serum PDGF-AB in pleural mesothelioma
-
Filiberti, R.; Marroni, P.; Neri, M.; Ardizzoni, A.; Betta, P.G.; Cafferata, M.A.; Canessa, P.A.; Puntoni, R.; Ivaldi, G.P.; Paganizzi, M. Serum PDGF-AB in pleural mesothelioma. Tumour Biol.2005, 26, 221-226.
-
(2005)
Tumour Biol
, vol.26
, pp. 221-226
-
-
Filiberti, R.1
Marroni, P.2
Neri, M.3
Ardizzoni, A.4
Betta, P.G.5
Cafferata, M.A.6
Canessa, P.A.7
Puntoni, R.8
Ivaldi, G.P.9
Paganizzi, M.10
-
106
-
-
33845924511
-
Expression of vascular endothelial growth factor in malignant mesothelioma
-
Aoe, K.; Hiraki, A.; Tanaka, T.; Gemba, K.; Taguchi, K.; Murakami, T.; Sueoka, N.; Kamei, T.; Ueoka, H.; Sugi, K.; Yoshino, T.; Kishimoto, T. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006, 26, 4833-4836
-
(2006)
Anticancer Res
, vol.26
, pp. 4833-4836
-
-
Aoe, K.1
Hiraki, A.2
Tanaka, T.3
Gemba, K.4
Taguchi, K.5
Murakami, T.6
Sueoka, N.7
Kamei, T.8
Ueoka, H.9
Sugi, K.10
Yoshino, T.11
Kishimoto, T.12
-
107
-
-
0035068834
-
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
-
Strizzi, L.; Catalano, A.; Vianale, G.; Orecchia, S.; Casalini, A.; Tassi, G.; Puntoni, R.; Mutti, L.; Procopio, A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 2001, 193, 468-475.
-
(2001)
J. Pathol.
, vol.193
, pp. 468-475
-
-
Strizzi, L.1
Catalano, A.2
Vianale, G.3
Orecchia, S.4
Casalini, A.5
Tassi, G.6
Puntoni, R.7
Mutti, L.8
Procopio, A.9
-
108
-
-
0034773992
-
EGFR family and its ligand in human cancer. Signalling mechanisms and therapeutic opportunities
-
Yarden, Y. EGFR family and its ligand in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37, S3-S8.
-
(2001)
Eur. J. Cancer.
, vol.37
-
-
Yarden, Y.1
-
109
-
-
0025330611
-
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody
-
Dazzi, H.; Hasleton, P.S.; Thatcher, N.; Wilkes, S.; Swindell, R.; Chatterjee, A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer 1990, 61, 924-926.
-
(1990)
Br. J. Cancer.
, vol.61
, pp. 924-926
-
-
Dazzi, H.1
Hasleton, P.S.2
Thatcher, N.3
Wilkes, S.4
Swindell, R.5
Chatterjee, A.K.6
-
110
-
-
33750313674
-
EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma
-
Edwards, J.G.; Swinson, D.E.; Jones, J.L.; Waller, D.A.; O'Byrne, K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54, 399-407.
-
(2006)
Lung Cancer
, vol.54
, pp. 399-407
-
-
Edwards, J.G.1
Swinson, D.E.2
Jones, J.L.3
Waller, D.A.4
O'Byrne, K.J.5
-
111
-
-
66349102769
-
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma
-
Pinton, G.; Brunelli, E.; Murer, B.; Puntoni, R.; Puntoni, M.; Fennell, D.A.; Gaudino, G.; Mutti, L.; Moro, L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69, 4598-4604.
-
(2009)
Cancer Res
, vol.69
, pp. 4598-4604
-
-
Pinton, G.1
Brunelli, E.2
Murer, B.3
Puntoni, R.4
Puntoni, M.5
Fennell, D.A.6
Gaudino, G.7
Mutti, L.8
Moro, L.9
-
112
-
-
0032758427
-
Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma
-
Soini, Y.; Kinnula, V.; Kaarteenaho-Wiik, R.; Kurttila, E.; Linnainmaa, K.; Pääkkö, P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res. 1999, 5, 3508-3515.
-
(1999)
Clin. Cancer Res.
, vol.5
, pp. 3508-3515
-
-
Soini, Y.1
Kinnula, V.2
Kaarteenaho-Wiik, R.3
Kurttila, E.4
Linnainmaa, K.5
Pääkkö, P.6
-
113
-
-
26444437808
-
Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma
-
Kokturk, N.; Firat, P.; Akay, H.; Kadilar, C.; Ozturk, C.; Zorlu, F.; Gungen, Y.; Emri, S. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005, 50, 189-198.
-
(2005)
Lung Cancer
, vol.50
, pp. 189-198
-
-
Kokturk, N.1
Firat, P.2
Akay, H.3
Kadilar, C.4
Ozturk, C.5
Zorlu, F.6
Gungen, Y.7
Emri, S.8
-
114
-
-
33847372487
-
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma
-
Gordon, G.J.; Mani, M.; Mukhopadhyay, L.; Dong, L.; Edenfield, H.R.; Glickman, J.N.; Yeap, B.Y.; Sugarbaker, D.J.; Bueno, R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J. Pathol. 2007, 211, 447-454.
-
(2007)
J. Pathol.
, vol.211
, pp. 447-454
-
-
Gordon, G.J.1
Mani, M.2
Mukhopadhyay, L.3
Dong, L.4
Edenfield, H.R.5
Glickman, J.N.6
Yeap, B.Y.7
Sugarbaker, D.J.8
Bueno, R.9
-
115
-
-
0038115843
-
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
-
Edwards, J.G.; McLaren, J.; Jones, J.L.; Waller, D.A.; O'Byrne, KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br. J. Cancer 2003, 88, 1553-1559.
-
(2003)
Br. J. Cancer.
, vol.88
, pp. 1553-1559
-
-
Edwards, J.G.1
McLaren, J.2
Jones, J.L.3
Waller, D.A.4
O'Byrne, K.J.5
-
116
-
-
0036278887
-
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma
-
Edwards, J.G.; Faux, S.P.; Plummer, S.M.; Abrams, K.R.; Walker, R.A.; Waller, D.A.; O'Byrne, K.J. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin. Cancer Res. 2002, 8, 1857-1862.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 1857-1862
-
-
Edwards, J.G.1
Faux, S.P.2
Plummer, S.M.3
Abrams, K.R.4
Walker, R.A.5
Waller, D.A.6
O'Byrne, K.J.7
-
117
-
-
22144439371
-
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma
-
O'Kane, S.L.; Cawkwell, L.; Campbell, A.; Lind, M.J. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur. J. Cancer 2005, 41, 1645-1648.
-
(2005)
Eur. J. Cancer.
, vol.41
, pp. 1645-1648
-
-
O'Kane, S.L.1
Cawkwell, L.2
Campbell, A.3
Lind, M.J.4
-
118
-
-
33750057002
-
Biology and management of malignant pleural mesothelioma
-
Zucali, P.A.; Giaccone, G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 2006, 42, 2706-2714.
-
(2006)
Eur. J. Cancer.
, vol.42
, pp. 2706-2714
-
-
Zucali, P.A.1
Giaccone, G.2
-
119
-
-
28444433731
-
Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
-
Jahan, T.; Gu, L.; Wang, X.; Kratzke, R.; Green, M.; Vokes, E.; Kindler, H. Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2005, 49, S221.
-
(2005)
Lung Cancer
, vol.49
-
-
Jahan, T.1
Gu, L.2
Wang, X.3
Kratzke, R.4
Green, M.5
Vokes, E.6
Kindler, H.7
-
120
-
-
17044387747
-
Thalidomide in patients with malignant pleural mesothelioma
-
Baas, P.; Boogerd, W.; Dalesio, O.; Haringhuizen, A.; Custers, F.; van Zandwijk, N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48, 291-296.
-
(2005)
Lung Cancer
, vol.48
, pp. 291-296
-
-
Baas, P.1
Boogerd, W.2
Dalesio, O.3
Haringhuizen, A.4
Custers, F.5
van Zandwijk, N.6
-
121
-
-
0003285752
-
SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study
-
Kindler, H.L.; Vogelzang, N.J.; Chien, K. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study. J. Clin. Oncol. 2001, 2, 1359.
-
(2001)
J. Clin. Oncol.
, vol.2
, pp. 1359
-
-
Kindler, H.L.1
Vogelzang, N.J.2
Chien, K.3
-
122
-
-
34548217698
-
Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307
-
Jänne, P.A.; Wang, X.F.; Krug, L.M.; Hodgson, L.; Vokes, E.E.; Kindler, H.L. Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307. Lung Cancer 2006, 54, S51.
-
(2006)
Lung Cancer
, vol.54
-
-
Jänne, P.A.1
Wang, X.F.2
Krug, L.M.3
Hodgson, L.4
Vokes, E.E.5
Kindler, H.L.6
-
123
-
-
0033392005
-
Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
-
Huang, S.M.; Harari, PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 1999, 17, 259-269.
-
(1999)
Invest. New Drugs.
, vol.17
, pp. 259-269
-
-
Huang, S.M.1
Harari, P.M.2
-
124
-
-
16844372990
-
Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
-
Cancer and Leukemia Group B (CALGB 30101)
-
Govindan, R.; Kratzke, R.A.; Herndon, J.E., II; Niehans, G.A.; Vollmer, R.; Watson, D.; Green, M.R.; Kindler, H.L. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 2005, 11, 2300-2304.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 2300-2304
-
-
Govindan, R.1
Kratzke, R.A.2
Herndon II, J.E.3
Niehans, G.A.4
Vollmer, R.5
Watson, D.6
Green, M.R.7
Kindler, H.L.8
-
125
-
-
34347273808
-
Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study
-
Garland, L.L.; Rankin, C.; Gandara, D.R. Rivkin, S.E.; Scott, K.M.; Nagle, R.B.; Klein-Szanto, A.J.; Testa, J.R.; Altomare, D.A.; Borden, E.C. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 2007, 25, 2406-2413.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 2406-2413
-
-
Garland, L.L.1
Rankin, C.2
Gandara, D.R.3
Rivkin, S.E.4
Scott, K.M.5
Nagle, R.B.6
Klein-Szanto, A.J.7
Testa, J.R.8
Altomare, D.A.9
Borden, E.C.10
-
126
-
-
21244464349
-
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
-
Kelly, W.K.; O'Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore- Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P.A.; Scher, H.; Richon, V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 3923-3931
-
-
Kelly, W.K.1
O'Connor, O.A.2
Krug, L.M.3
Chiao, J.H.4
Heaney, M.5
Curley, T.6
Macgregore-Cortelli, B.7
Tong, W.8
Secrist, J.P.9
Schwartz, L.10
Richardson, S.11
Chu, E.12
Olgac, S.13
Marks, P.A.14
Scher, H.15
Richon, V.M.16
-
127
-
-
2942708234
-
The role of proteasome inhibitors in solid tumors
-
Park, D.J.; Lenz, H.J. The role of proteasome inhibitors in solid tumors. Ann. Med. 2004, 36, 296-303.
-
(2004)
Ann. Med.
, vol.36
, pp. 296-303
-
-
Park, D.J.1
Lenz, H.J.2
-
128
-
-
20444389044
-
Apoptosis regulation and drug resistance in malignant pleural mesothelioma
-
Zangemeister-Wittke, U.; Hopkins-Donaldson, S. Apoptosis regulation and drug resistance in malignant pleural mesothelioma. Lung Cancer 2005, 49, 105-108.
-
(2005)
Lung Cancer
, vol.49
, pp. 105-108
-
-
Zangemeister-Wittke, U.1
Hopkins-Donaldson, S.2
-
129
-
-
33847401904
-
Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma
-
Gordon, G.J.; Mani, M.; Mukhopadhyay, L.; Dong, L.; Yeap, B.Y.; Sugarbaker, D.J.; Bueno, R. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J. Pathol. 2007, 211, 439-446.
-
(2007)
J. Pathol.
, vol.211
, pp. 439-446
-
-
Gordon, G.J.1
Mani, M.2
Mukhopadhyay, L.3
Dong, L.4
Yeap, B.Y.5
Sugarbaker, D.J.6
Bueno, R.7
-
130
-
-
0036621573
-
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
-
Smythe, W.R.; Mohuiddin, I.; Ozveran, M.; Cao, X.X. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J. Thorac. Cardiovasc. Surg. 2002, 123, 1191-1198.
-
(2002)
J. Thorac. Cardiovasc. Surg.
, vol.123
, pp. 1191-1198
-
-
Smythe, W.R.1
Mohuiddin, I.2
Ozveran, M.3
Cao, X.X.4
-
131
-
-
24944539840
-
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth
-
Altomare, D.A.; You, H.; Xiao, G.H.; Ramos-Nino, M.E.; Skele, K.L.; De Rienzo, A.; Jhanwar, S.C.; Mossman, B.T.; Kane, A.B.; Testa, J.R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24, 6080-6089.
-
(2005)
Oncogene
, vol.24
, pp. 6080-6089
-
-
Altomare, D.A.1
You, H.2
Xiao, G.H.3
Ramos-Nino, M.E.4
Skele, K.L.5
de Rienzo, A.6
Jhanwar, S.C.7
Mossman, B.T.8
Kane, A.B.9
Testa, J.R.10
-
132
-
-
31544439933
-
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
-
Hassan, R.; Remaley, A.T.; Sampson, M.L.; Zhang, J.; Cox, D.D.; Pingpank, J.; Alexander, R.; Willingham, M.; Pastan, I.; Onda, M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12, 447-453.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 447-453
-
-
Hassan, R.1
Remaley, A.T.2
Sampson, M.L.3
Zhang, J.4
Cox, D.D.5
Pingpank, J.6
Alexander, R.7
Willingham, M.8
Pastan, I.9
Onda, M.10
-
133
-
-
65649133121
-
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment
-
Grigoriu, B.D.; Chahine, B.; Vachani, A.; Gey, T.; Conti, M.; Sterman, D.H.; Marchandise, G.; Porte, H.; Albelda, S.M.; Scherpereel, A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am. J. Respir. Crit. Care Med. 2009, 179, 950-954.
-
(2009)
Am. J. Respir. Crit. Care Med.
, vol.179
, pp. 950-954
-
-
Grigoriu, B.D.1
Chahine, B.2
Vachani, A.3
Gey, T.4
Conti, M.5
Sterman, D.H.6
Marchandise, G.7
Porte, H.8
Albelda, S.M.9
Scherpereel, A.10
|